Tivic Health acquires exclusive worldwide license for Statera's TLR5 agonist Entolimod for ARS

Valion Bio, Inc.

License fee of $1.5M ($300K cash + $1.2M in stock and preferred) for exclusive rights to Entolimod for ARS.
Potential milestones up to $1.75M for ARS and $6.5M for additional indications, total $8.25M.
Exclusive option to expand license to five additional indications including Lymphocyte Exhaustion and Neutropenia.
Entolimod has FDA Fast Track & Orphan Drug designation; prior investment $140M; potential BLA filing within 24 months.
Statera gets Board seat nomination; Tivic to hold stockholder vote on Series A conversion within 120 days.

item 1.01 item 5.03 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.